Glucagon-like peptide-1, or GLP-1, is a naturally occurring intestinal hormone involved in glucose regulation, appetite, and digestion
Rybelsus is available only by prescription
Individuals with type 1 diabetes, thyroid cancer, multiple endocrine neoplasia, or end stage kidney disease at any time until cohort entry or individuals with dialysis or the latest eGFR 70 years, by males versus females, by insulin use, by atherosclerotic cardiovascular disease (i.e., myocardial infraction, angina, coronary artery disease, coronary revascularization, peripheral artery disease, aortic atherosclerotic disease, or cerebrovascular disease), by renal insufficiency (i.e., chronic kidney disease or the latest eGFR 70 years (HR [95% CI]: 0.95 [0.831.08])
This was a GLP-1-based therapy, mechanistically, that did not influence cardiovascular risk